Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the second quarter of 2025 and will host a corporate update conference call on November 12, 2025 [1]. Company Overview - Dyadic Applied BioSolutions is a global biotechnology company that utilizes proprietary microbial platforms to produce recombinant proteins for various markets including life sciences, food and nutrition, and bio-industrial applications [4]. - The company’s C1 and Dapibus™ expression systems enable flexible, cost-effective manufacturing, forming the basis of a growing portfolio of commercial and partnered programs [4]. Conference Call Details - The conference call is scheduled for November 12, 2025, at 5:00 p.m. Eastern Time, with dial-in numbers provided for both toll-free and international participants [2]. - A webcast link for the conference call is available, and an archive will be accessible within 24 hours post-event [2]. Investor Relations - Questions for management during the Q&A session can be submitted via email prior to the conference call [3]. - For further information, the company’s website offers resources in the Investor Relations section [2][4].

Core Insights - Dyadic International, Inc. is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins for non-therapeutic applications in life sciences, food and nutrition, and industrial biotechnology [1][2] Company Overview - Dyadic utilizes proprietary microbial platforms to produce recombinant proteins, which are sold or licensed to partners across various markets [2] - The company's C1 and Dapibus™ expression systems support flexible, cost-effective manufacturing, forming the foundation of a growing portfolio of commercial and partnered programs [2] Upcoming Events - Joe Hazelton, President & COO of Dyadic, will present at several upcoming conferences, including: - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025 [1] - BioProcess International BPI East from September 15-18, 2025 [1] - Sidoti Small Cap Investor Event from September 17-18, 2025 [1] - The management team is open to connecting with investors, analysts, and industry partners during these events [1]

Core Viewpoint - Dyadic International, Inc. is set to report its financial results for the second quarter of 2025 and will host a corporate update conference call on August 13, 2025 [1] Group 1: Financial Reporting - The company will announce its financial results for Q2 2025 on August 13, 2025 [1] - A conference call will take place at 5:00 p.m. Eastern Time on the same day [2] - Dial-in numbers for the conference call are provided, including a toll-free option and an international number [2] Group 2: Company Overview - Dyadic is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins [1][4] - The company utilizes proprietary gene expression platforms for applications in life sciences, food and nutrition, and industrial biotechnology [1][4] - Dyadic's C1 and Dapibus™ expression systems support flexible and cost-effective manufacturing, forming the basis of its commercial and partnered programs [4]

Core Viewpoint - Dyadic International, Inc. has announced a public offering of 6,052,000 shares of common stock at a price of $0.95 per share, expecting gross proceeds of approximately $5.75 million before expenses [1][2]. Group 1: Offering Details - The public offering is managed by Craig-Hallum Capital Group LLC, and the closing is anticipated on August 1, 2025, subject to customary conditions [1][2]. - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including product development and sales and marketing [2]. Group 2: Company Background - Dyadic International is a global biotechnology company that focuses on scalable production of precision-engineered functional input proteins for various applications in life sciences, food and nutrition, and industrial biotechnology [1][5]. - The company utilizes proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, to produce high-quality recombinant proteins for partners in multiple markets [5].

Core Viewpoint - Dyadic International, Inc. has announced the pricing of its public offering of 6,052,000 shares of common stock, with the closing expected on August 1, 2025, subject to customary conditions [1]. Company Overview - Dyadic International, Inc. is a global biotechnology company focused on scalable production of high-value, precision-engineered functional input proteins for life sciences, food and nutrition, and industrial biotechnology applications [1][5]. - The company utilizes proprietary gene expression platforms to produce recombinant proteins, which are sold or licensed to partners across various markets [5]. Offering Details - The public offering is being managed solely by Craig-Hallum Capital Group LLC [2]. - The net proceeds from the offering will be used for working capital and general corporate purposes, including product development, sales, and marketing [2]. - The offering is conducted under an effective shelf registration statement filed with the SEC [3]. Contact Information - For inquiries, Dyadic Applied BioSolutions can be contacted through Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com [8].

Core Viewpoint - Dyadic International, Inc. has initiated an underwritten public offering of common stock to raise funds for working capital and general corporate purposes, including product development and marketing efforts [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no guarantee regarding its completion or the specific terms of the offering [1]. - Craig-Hallum Capital Group LLC is the sole managing underwriter for this offering [2]. - The offering is being conducted under an effective shelf registration statement filed with the SEC, with a preliminary prospectus supplement to be filed [3]. Group 2: Company Overview - Dyadic is a global biotechnology company that specializes in the scalable production of precision-engineered functional input proteins for various applications in life sciences, food and nutrition, and industrial biotechnology [1][5]. - The company utilizes proprietary gene expression platforms, specifically its C1 and Dapibus™ systems, to produce high-quality recombinant proteins [5].